Trailhead Biosystems is pioneering the development of cell-based therapeutics using machine learning and bioinformatics. Trailhead's High Dimensional Design of Experiments (HD-DoE) platform merges developmental biology and cell therapeutics with advanced robotics, computerized experimental design, and analysis to perform process-specific parameter optimization in the development of cell therapies.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 11/10/20 | $6,600,000 | Series A | ||
| 05/06/25 | $20,000,000 | Venture |
MAK Capital | undisclosed |
